- Previous Close
7.40 - Open
7.41 - Bid 8.10 x 100
- Ask 9.50 x 100
- Day's Range
7.08 - 7.70 - 52 Week Range
7.08 - 24.15 - Volume
20,622 - Avg. Volume
25,633 - Market Cap (intraday)
132.413M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.71 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.
kalaristx.comRecent News: KLRS
View MorePerformance Overview: KLRS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KLRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KLRS
View MoreValuation Measures
Market Cap
134.47M
Enterprise Value
141.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-681.04%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-69.17M
Diluted EPS (ttm)
-2.71
Balance Sheet and Cash Flow
Total Cash (mrq)
1.64M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-18.82M